+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID07178847

Evaluating Circulating DNA to Detect Residual Disease After Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Led by Centre Jean Perrin · Updated on 2026-09-11

59

Participants Needed

4

Research Sites

117 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying circulating DNA cDNA as a potential biomarker to detect residual disease following chemoradiotherapy in patients with locally advanced head and neck squamous cell carcinoma. This ancillary clinical trial focuses on whether cDNA can identify residual disease three months after treatment by comparing cDNA detection results with clinical and radiological assessments. Participants will undergo blood sampling, where 18 mL of blood is collected at one and three months after completing chemoradiotherapy. These blood samples are used to assess the presence and kinetics of circulating DNA, and researchers will also study mutational profiles and HPV genotypes in relation to the tumor and ctDNA at diagnosis. During the trial, participants provide blood samples at specified times and are monitored for objective response to treatment and survival outcomes. Researchers measure cDNA detection and compare it with clinical responses at one and three months post-treatment. The study is conducted alongside the main Neck-TAR study, and participation involves blood draws and follow-up evaluations up to 27 months after treatment to assess progression-free and overall survival.

CONDITIONS

Brief Title

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Research Team

A

Angeline GINZAC COUVÉ Project manager, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here